نتائج البحث - "Katja Seipel"

31

Data from Inactivation of the p53–KLF4–CEBPA Axis in Acute Myeloid Leukemia

المؤلفون: Thomas Pabst, Beatrice U. Mueller, Christina Meinken, Marie-Ange Bozzini, Miguel Teixera Marques, Katja Seipel

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56f69e058eb044d689fb94a86194be0dTest
https://doi.org/10.1158/1078-0432.c.6524360Test

32

Supplementary Material Figure legend to Figure S1 and Figure S2 from Inactivation of the p53–KLF4–CEBPA Axis in Acute Myeloid Leukemia

المؤلفون: Thomas Pabst, Beatrice U. Mueller, Christina Meinken, Marie-Ange Bozzini, Miguel Teixera Marques, Katja Seipel

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77e4e7f6b11a325921801179e537bb61Test
https://doi.org/10.1158/1078-0432.22459958.v1Test

33

Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia

المؤلفون: Ulrike Bacher, Laura Flückiger, Thomas Pabst, Carolyn Graber, Katja Seipel

المصدر: International Journal of Molecular Sciences, Vol 22, Iss 8092, p 8092 (2021)
International Journal of Molecular Sciences
Volume 22
Issue 15
Seipel, Katja; Graber, Carolyn; Flückiger, Laura; Bacher, Vera; Pabst, Thomas (2021). Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia. International journal of molecular sciences, 22(15) MDPI 10.3390/ijms22158092 <http://dx.doi.org/10.3390/ijms22158092Test>

مصطلحات موضوعية: 0301 basic medicine, chemistry.chemical_compound, 0302 clinical medicine, fluids and secretions, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, STAT5 Transcription Factor, Medicine, MCL1, Midostaurin, Biology (General), Spectroscopy, Trametinib, Kinase, ten-eleven translocation-2 (TET2), Myeloid leukemia, hemic and immune systems, General Medicine, 3. Good health, Computer Science Applications, DNA-Binding Proteins, Leukemia, Myeloid, Acute, Chemistry, myeloid leukemia cell differentiation protein (MCL1), 030220 oncology & carcinogenesis, embryonic structures, FLT3 Inhibitor, Combination therapy, QH301-705.5, tumor suppressor p53 (TP53), 610 Medicine & health, Thiophenes, Article, Catalysis, Dioxygenases, Inorganic Chemistry, 03 medical and health sciences, signal transducer and activator of transcription 5 (STAT5), acute myeloid leukemia (AML), Cell Line, Tumor, Proto-Oncogene Proteins, Humans, hematological malignancies, Physical and Theoretical Chemistry, Molecular Biology, QD1-999, FMS-like tyrosine kinase 3 (FLT3), business.industry, Venetoclax, Tumor Suppressor Proteins, Organic Chemistry, Pyrimidines, 030104 developmental biology, fms-Like Tyrosine Kinase 3, chemistry, Cancer research, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a86caaa2cbf92ffdc34d64b704e8471Test
https://www.mdpi.com/1422-0067/22/15/8092Test

34

Cancer Prognosis According to Parthanatos Features

المؤلفون: Katja Seipel, Alexandre Theocharides, Bruktawit Maru, Thomas Pabst, Maureen McKeague, Peter J. M. Valk, Nathan W. Luedtke, Alessandra Messikommer

مصطلحات موضوعية: Chemotherapy, Anthracycline, business.industry, medicine.medical_treatment, Cancer, Myeloid leukemia, medicine.disease, Olaparib, chemistry.chemical_compound, chemistry, Cancer cell, medicine, Cytarabine, Cancer research, Idarubicin, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::b9e18174171c7986b9deb29ab5cb243eTest
https://doi.org/10.1101/2021.05.24.445484Test

35

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia

المؤلفون: Ulrike Bacher, Basil Kopp, Thomas Pabst, Katja Seipel

المصدر: Cancers, Vol 13, Iss 581, p 581 (2021)
Cancers
Volume 13
Issue 3
Seipel, Katja; Kopp, Basil; Bacher, Ulrike; Pabst, Thomas (2021). BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers, 13(3) MDPI AG 10.3390/cancers13030581 <http://dx.doi.org/10.3390/cancers13030581Test>

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, NPM1, CD34, 610 Medicine & health, BMI1 Inhibitor PTC596, myeloid cell leukemia 1 (MCL1), lcsh:RC254-282, Article, 03 medical and health sciences, meningioma 1 (MN1), 0302 clinical medicine, acute myeloid leukemia (AML), hemic and lymphatic diseases, Medicine, MCL1, neoplasms, Trametinib, Acute leukemia, business.industry, MEK inhibitor, Myeloid leukemia, myelodysplastic syndrome (MDS), lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1), 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, tumor suppressor protein 53 (TP53), Cancer research, business, hematopoietic progenitor cell antigen cluster of differentiation 34 (CD34)